柴银亚甲方治疗风热痰阻型亚急性甲状腺炎的疗效及对疼痛因子、免疫功能指标、甲状腺功能指标的影响OA
Effect of Chaiyinya sub-party A in the treatment of subacute thyroiditis with wind,heat and phsputum obstruction and its influence on pain factors,immune function indexes and thyroid function indexes
目的 分析柴银亚甲方治疗风热痰阻型亚急性甲状腺炎的疗效及对疼痛因子、免疫功能指标、甲状腺功能指标的影响.方法 选取2023年7月至2024年7月该院收治的100例风热痰阻型亚急性甲状腺炎患者作为研究对象,采用随机数字表法分为基础组和柴银亚甲方组,每组50例.基础组给予常规西医治疗,柴银亚甲方组在基础组治疗的基础上给予柴银亚甲方治疗,基础组和柴银亚甲方组均连续治疗4周.疗程结束后比较基础组和柴银亚甲方组临床疗效;比较基础组和柴银亚甲方组治疗前后中医证候(发热、咽痛、颈前肿大、头痛、甲状腺疼痛、声音嘶哑)积分;检测所有患者免疫功能指标[补体C3、免疫球蛋白(Ig)A、淀粉样蛋白A(SAA)、肿瘤坏死因子(TNF)-β]、疼痛因子[血清前列腺素E2(E2)、缓激肽]、甲状腺功能指标[促甲状腺激素(TSH)、游离甲状腺素(FT4)、甲状腺球蛋白抗体(TgAb)、游离三碘甲状腺原氨酸(FT3)]水平;记录所有患者消肿时间、疼痛消退时间;记录所有患者治疗期间不良反应发生情况;用药后随访3个月,记录所有患者复发情况.结果 基础组脱落2例,最终纳入48例;柴银亚甲方组脱落3例,最终纳入47例.柴银亚甲方组总有效率为95.74%,高于基础组的79.17%,差异有统计学意义(P<0.05).基础组和柴银亚甲方组治疗后发热、咽痛、颈前肿大、头痛、甲状腺疼痛、声音嘶哑积分均低于治疗前,且柴银亚甲方组治疗后发热、咽痛、颈前肿大、头痛、甲状腺疼痛、声音嘶哑积分均低于基础组,差异均有统计学意义(P<0.05).基础组和柴银亚甲方组治疗后补体C3、IgA、SAA、TNF-β水平均低于治疗前,且柴银亚甲方组治疗后补体C3、IgA、SAA、TNF-β水平均低于基础组,差异均有统计学意义(P<0.05).基础组和柴银亚甲方组治疗后E2、缓激肽水平均低于治疗前,且柴银亚甲方组治疗后E2、缓激肽水平均低于基础组,差异均有统计学意义(P<0.05).基础组和柴银亚甲方组治疗后FT4、TgAb、FT3水平均低于治疗前,且柴银亚甲方组治疗后FT4、TgAb、FT3水平均低于基础组,差异均有统计学意义(P<0.05);基础组和柴银亚甲方组治疗后TSH水平均高于治疗前,且柴银亚甲方组治疗后TSH水平高于基础组,差异均有统计学意义(P<0.05).柴银亚甲方组治疗后消肿时间、疼痛消退时间均短于基础组,差异均有统计学意义(P<0.05).基础组和柴银亚甲方组治疗期间均无明显不良反应发生.随访3个月后,柴银亚甲方组复发率(2.13%)低于基础组(16.67%),差异有统计学意义(P<0.05).结论 柴银亚甲方治疗风热痰阻型亚急性甲状腺炎,可降低炎症因子、疼痛因子水平,调节免疫功能,改善甲状腺功能,提升临床疗效,且复发率较低,安全性较高.
Objective To analyze the efficacy of Chaiyinya sub-party A in the treatment of subacute thy-roiditis with wind,heat and phsputum obstruction and its influence on pain factors,immune function indexes and thyroid function indexes.Methods A total of 100 patients with subacute thyroiditis admitted to the hospi-tal from July 2023 to July 2024 were selected as the research objects,and they were divided into the basic group and the Chaiyin sub-party A group by random number table method,with 50 cases in each group.The basic treatment group was treated with conventional western medicine,and the Chaiyin sub-party A group was treated with Chaiyin sub-party A on the basis of the basic treatment group.The basic treatment group and Chaiyin sub-party A group were treated for 4 weeks.After the treatment,the clinical efficacy was compared between the basic group and the Chaiyin sub-party A group.The scores of TCM syndromes(fever,sore throat,neck enlargement,headache,thyroid pain,hoarseness)were compared between the basic group and the Chaiyin sub-party A group before and after treatment.The levels of immune function indexes[complement C3,immunoglobulin(Ig)A,amyloid A(SAA),tumor necrosis factor(TNF)-β]and pain factors[serum pros-taglandin E2(E2),bradykinin]were detected in all patients.The levels of inflammatory indicators and thyroid function indicators[thyroid stimulating hormone(TSH),free thyroxine(FT4),thyroglobulin antibody(TgAb),free triiodothyronine(FT3)]were detected in all patients.The swelling time and pain resolution time of all patients were recorded.The adverse reactions of all patients during treatment were recorded.All patients were followed up for 3 months after treatment,and the recurrence of all patients was recorded.Results In the basic group,2 cases dropped out,and 48 cases were finally included.In Chaiyin sub-party A group,3 cases dropped out,and 47 cases were finally included.The total effective rate of Chaiyin sub-party A group was 95.74%,which was higher than 79.17%of the basic group,and the difference was statistically sig-nificant(P<0.05).After treatment,the scores of fever,sore throat,anterior neck swelling,headache,thyroid pain and hoarseness in the basic group and the Chaiyin sub-party A group were lower than those before treat-ment,and the scores of fever,sore throat,anterior neck swelling,headache,thyroid pain and hoarseness in the Chaiyin sub-party A group were lower than those in the basic group,and the differences were statistically sig-nificant(P<0.05).After treatment,the levels of complement C3,IgA,SAA,TNF-β in the basic group and the Chaiyin sub-party A group were lower than those before treatment,and the levels of complement C3,IgA,SAA,TNF-β in the Chaiyin sub-party A group were lower than those in the basic group,and the differences were statistically significant(P<0.05).The levels of E2,bradykinin in the basic group and the Chaiyin sub-party A group after treatment were lower than those before treatment,and the levels of E2 bradykinin in the Chaiyin sub-party A group after treatment were lower than those in the basic group,and the differences were statistically significant(P<0.05).After treatment,the levels of FT4,TgAb and FT3 in the basic group and the Chaiyin sub-party A group were lower than those before treatment,and the levels of FT4,TgAb and FT3 in the Chaiyin sub-party A group were lower than those in the basic group,and the differences were statistical-ly significant(P<0.05).The TSH level of the basic group and the Chaiyin sub-party A group after treatment was higher than that before treatment,and the TSH level of the Chaiyin sub-party A group after treatment was higher than that of the basic group,and the differences were statistically significant(P<0.05).After treatment,the swelling time and pain subsiding time of the Chaiyin sub-party A group were shorter than those of the basic group,and the differences were statistically significant(P<0.05).No obvious adverse reactions occurred in the basic group and the Chaiyin sub-party A group during the treatment.After 3 months of follow-up,the recurrence rate of Chaiyin sub-party A group(2.13%)was lower than that of basic group(16.67%),and the difference was statistically significant(P<0.05).Conclusion Chaiyin sub-party A in the treatment of subacute thyroiditis can decrease the levels of inflammatory factors and pain factors,regulate immune func-tion,improve thyroid function,improve clinical efficacy,with low recurrence rate and high safety.
邵帅;孙佳佳;石天昱;张军
河北省唐山市中医医院中医内科,河北 唐山 063000河北省唐山市中医医院中医内科,河北 唐山 063000河北省唐山市中医医院中医内科,河北 唐山 063000河北省唐山市中医医院中医内科,河北 唐山 063000
医药卫生
柴银亚甲方亚急性甲状腺炎甲状腺功能炎症因子疼痛因子免疫功能
Chaiyin sub-party Asubacute thyroiditisthyroid functioninflammatory factorpain factorimmune function
《检验医学与临床》 2026 (1)
49-56,8
河北省中医药管理局科研计划项目(2021400).
评论